Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of guselkumab for recalcitrant oral ulcers in Behçet’s disease
KCT0010930Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of guselkumab in Behçet's disease (BD), sponsored by Janssen Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on KCT0010930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010930.